|
SEVERE ACUTE RESPIRATORY
SYNDROM (SARS) What Are We Doing About It? Dateline: May 7,
2003 By Tamar Love
Severe acute respiratory syndrome
(SARS), a highly contagious and sometimes fatal respiratory
illness that has been reported in more than 25 countries, is
quickly becoming a real concern. While SARS exposure has still
been primarily limited to Southeast Asian countries, the rapid
spread of the syndrome has caused concern
worldwide.
While there isn't yet an
insurance industry response to SARS, it is realistic to assume
that if the syndrome continues to spread, insurance agents
will need to get up to speed on SARS, its treatments and new
developments in prevention.
How Is SARS
Spread? According to the Center for Disease Control
(CDC), SARS appears to spread by close person-to-person
contact or from direct contact with infectious material from a
person who has SARS. Scientists at the CDC and other
laboratories have detected infection by a coronavirus in
patients with SARS. Sequencing of the virus genome by the CDC
has confirmed that this infectious agent is a previously
unrecognized strain of the virus.
Where Has SARS Been
Reported? While SARS has been reported in the United
States, most cases have been traced to people who recently
have traveled to China, Hong Kong, Singapore and Vietnam.
Because SARS is highly contagious, health officials are
watching the disease closely and are hoping that the more
information available to the public, the better the chances
are of containing this potentially fatal disease. One reliable
resource is MayoClinic.com. Since
its identification in February of this year, SARS has affected
more than 5,300 patients worldwide and resulted in more than
355 deaths.
How is SARS
Treated? Although most people with SARS have recovered,
it is still unknown why some people die from the disease, and
there is no 100% effective treatment for people infected with
the syndrome. i-STAT
Corporation, a leading manufacturer of point-of-care
diagnostic systems for blood analysis, has responded to an
emergency order for 395 i-STAT Portable Clinical Analyzers,
the system used to monitor critical pulmonary function changes
(i.e., acute respiratory failure) in ICU patients, by
stepping-up shipments of their product to health-care
facilities in China. It is hoped that the i-STAT system can
help doctors better monitor patients affected by
SARS.
Is There a Test for
SARS? Until now, there hasn't been an effective
diagnostic test for SARS. However, Focus
Technologies, the Cypress, California-based developer and
provider of infectious disease testing services and diagnostic
products, recently developed a first-generation, real-time PCR
test designed to detect the presence of the coronavirus
associated with the development of SARS in patients. Focus
Technologies also offers viral culture test methods capable of
growing the SARS coronavirus as well as other viral
respiratory pathogens.
How Can We Prevent the Spread
of SARS? Until a vaccine has been developed, the only
effective way to prevent the spread of SARS is to prevent
contact with persons infected with it. FLIR Systems, has developed a
thermal-imaging security camera, used at airports, hospitals
and other locations in Taiwan and Korea. These cameras will be
used to help detect fever, a possible precursor to severe
acute respiratory syndrome (SARS). The cameras can accurately
measure temperature and can be programmed to detect body
temperature. Airline passengers and visitors to hospitals and
other locations will be asked to look into the infrared camera
for a matter of seconds, which allows the camera to record
facial temperature. What is the U.S. Government Doing About
SARS? On May 7, 2003, the U.S. Subcommittee on
Oversight and Investigations held a hearing entitled "SARS:
Assessment, Outlook and Lessons Learned," at which Dr.
Lonberg, representing Medarex and Massachusetts
Biologic Laboratories (MBL) of the University of
Massachusetts, provided testimony addressing the potential of
antibodies as a distinct class of biopharmaceutical
therapeutics that could be developed to combat infectious
diseases like severe acute respiratory syndrome (SARS).
Dr. Burger, representing AVI Biopharma, presented
information AVI's rapid response NEUGENE(R) antisense
platform, an experimental SARS antisense compound developed
within 10 days of receiving the genetic sequence of the virus
from several sources including the Centers for Disease Control
and World Health Organization (WHO) laboratories.
Other expert witnesses included
members from the U.S. Department
of Health and Human Services, the U.S. Centers for Disease
Control and Prevention (CDC), the National Institute of Allergy
and Infectious Diseases, the U.S. Food and Drug
Administration, the U.S.
General Accounting Office and various public health
organizations and drug research companies.
Once the findings of the hearing
have been processed, the Oversight subcommittee will issue a
report, which can then be used by government health
organizations to inform the public of potential options for
prevention, treatment and vaccination.
top
of
page |